Nab-paclitaxel and Cisplatin is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Hebei Medical University Fourth Hospital (1). The most-studied condition is Esophageal Squamous Cell Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03964753 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
|
Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | China |
|
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
NCT07452601 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
|
Phase 2 | Recruiting | Tang-Du Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hebei Medical University Fourth Hospital | 1 |
| Tang-Du Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Nab-paclitaxel and Cisplatin as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hebei Medical University Fourth Hospital (1) and Tang-Du Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nab-paclitaxel and Cisplatin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nab-paclitaxel and Cisplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nab-paclitaxel and Cisplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.